Survival implication of lymphadenectomy in patients surgically treated for apparent early-stage uterine serous carcinoma.
Endometrial Neoplasms
Gynecology
Lymphadenectomy
Survival
Therapeutics
Journal
Journal of gynecologic oncology
ISSN: 2005-0399
Titre abrégé: J Gynecol Oncol
Pays: Korea (South)
ID NLM: 101483150
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
26
11
2019
revised:
17
04
2020
accepted:
18
04
2020
entrez:
19
8
2020
pubmed:
19
8
2020
medline:
2
9
2021
Statut:
ppublish
Résumé
Uterine serous carcinoma (USC) is a rare highly aggressive disease. In the present study, we aimed to investigate the survival implication of the systematic lymphadenectomy in patients who underwent surgery for apparent early-stage USC. Consecutive patients with apparent early-stage USC surgically treated at six Italian referral cancer centers were analyzed. A comparison was made between patients who underwent retroperitoneal staging including at least pelvic lymphadenectomy "LND" vs. those who underwent hysterectomy alone "NO-LND". Baseline, surgical and oncological outcomes were analyzed. Kaplan- Meier curves were calculated for disease-free survival (DFS) and disease-specific survival (DSS). Associations were evaluated with Cox proportional hazard regression and summarized using hazard ratio (HR). One hundred forty patients were analyzed, 106 LND and 34 NO-LND. NO-LND group (compared to LND group) included older patients (median age, 73 vs.67 years) and with higher comorbidities (median Charlson Comorbidity Index, 6 vs. 5) (p<0.001). No differences in terms of recurrence rate (LND vs. NO-LND, 33.1% vs. 41.4%; p=0.240) were observed. At Cox regression analysis lymphadenectomy did not significantly influence DFS (HR=0.59; 95% confidence interval [CI]=0.32-1.08; p=0.09), and DSS (HR=0.14; 95% CI=0.02-1.21; multivariable analysis p=0.07). Positive node was independently associated with worse DFS (HR=6.22; 95% CI=3.08-12.60; p<0.001) and DSS (HR=5.51; 95% CI=2.31-13.10; p<0.001), while adjuvant chemotherapy was associated with improved DFS (HR=0.38; 95% CI=0.17-0.86; p=0.02) and age was independently associated with worse DSS (HR=1.07; 95% CI=1.02-1.13; p<0.001). Although lymphadenectomy did not show survival benefits in patients who underwent surgery for apparent early-stage USC, the presence of lymph node metastasis was the main adverse prognostic factors, supporting the prognostic role of the retroperitoneal staging also in this histological subtype.
Identifiants
pubmed: 32808495
pii: 31.e64
doi: 10.3802/jgo.2020.31.e64
pmc: PMC7440990
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e64Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology.
Déclaration de conflit d'intérêts
No potential conflict of interest relevant to this article was reported.
Références
Int J Gynecol Cancer. 2018 Jul;28(6):1138-1144
pubmed: 29621127
Gynecol Oncol. 2019 Feb;152(2):304-309
pubmed: 30503049
Int J Gynecol Cancer. 2016 Jan;26(1):2-30
pubmed: 26645990
Ann Surg Oncol. 2012 Jan;19(1):259-67
pubmed: 21695563
Gynecol Oncol. 1993 Jan;48(1):32-7
pubmed: 8423019
Gynecol Oncol. 2017 Aug;146(2):234-239
pubmed: 28528918
Brachytherapy. 2019 Jan - Feb;18(1):38-43
pubmed: 30316723
Gynecol Oncol. 2005 Mar;96(3):579-82
pubmed: 15721397
J Natl Cancer Inst. 2008 Dec 3;100(23):1707-16
pubmed: 19033573
Semin Diagn Pathol. 2014 May;31(3):205-15
pubmed: 24951284
Lancet Oncol. 2017 Mar;18(3):384-392
pubmed: 28159465
Int J Gynecol Cancer. 2019 Jan;29(1):60-67
pubmed: 30640685
Gynecol Oncol. 2008 Apr;109(1):11-8
pubmed: 18304622
Am J Obstet Gynecol. 2018 Nov;219(5):463.e1-463.e12
pubmed: 30086293
J Clin Epidemiol. 1994 Nov;47(11):1245-51
pubmed: 7722560
Lancet. 2009 Jan 10;373(9658):125-36
pubmed: 19070889
Gynecol Oncol. 2008 Nov;111(2 Suppl):S44-50
pubmed: 18760450
Gynecol Oncol. 2012 Dec;127(3):651-61
pubmed: 23000148
Obstet Gynecol. 2018 Feb;131(2):304-311
pubmed: 29324598
Lancet Oncol. 2019 Sep;20(9):1273-1285
pubmed: 31345626
Contemp Clin Trials. 2006 Aug;27(4):353-63
pubmed: 16678497
Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):208-16
pubmed: 12909235
Am J Obstet Gynecol. 2008 Feb;198(2):218.e1-6
pubmed: 18226630
Obstet Gynecol. 2014 Aug;124(2 Pt 1):307-15
pubmed: 25004343
J Clin Oncol. 2009 Nov 10;27(32):5331-6
pubmed: 19805679
Gynecol Oncol. 2005 Dec;99(3):557-63
pubmed: 16154185
Gynecol Oncol. 2004 Dec;95(3):593-6
pubmed: 15581969
Gynecol Oncol. 1994 Sep;54(3):264-8
pubmed: 8088602
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398